|
|
Article: Avant Reports Positive Data In Cholera Vaccine Phase II.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Two months after selling some of the royalty rights to its rotavirus vaccine so the company could focus on other programs, Avant Immunotherapeutics Inc. reported preliminary success in Phase II with its vaccine for another diarrheal disease, cholera, in infants and children.
Avant's stock (NASDAQ:AVAN) closed Tuesday at $1.41, up 3 cents after trading as high as $1.56.
The single-dose, oral vaccine already had been shown to work in adults. The latest results show it to be well tolerated and highly effective in children aged 9 months to 5 years, with 77 percent generating immune responses.
Most significant were ...